Century Therapeutics is a biotechnology company developing off-the-shelf allogeneic cell therapies derived from induced pluripotent stem cells to treat autoimmune diseases and cancer. The company's platform integrates iPSC generation, CRISPR-mediated gene editing, proprietary Allo-Evasion™ technology to prevent immune rejection, and scalable manufacturing capabilities to produce multiple mature cell types including beta islet cells, T cells, and natural killer cells. The company targets major unmet medical needs in Type 1 Diabetes, where patients currently rely on insulin therapy with suboptimal control, and B-cell-mediated autoimmune diseases such as systemic lupus erythematosus and idiopathic inflammatory myopathy, where existing therapies demonstrate limited efficacy. Revenue will be generated upon successful clinical development, regulatory approval, and commercial adoption of its cell therapy candidates, potentially augmented through strategic partnerships and licensing agreements.